Versant Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Versant Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75K	Buy	3,257 +184	+6%	+$218	﹤0.01%	2487
2026 Q1	$2.33K	Buy	3,073 +1,050	+52%	+$1.22K	﹤0.01%	2545
2025 Q4	$2.73K	Buy	+2,023	New	+$3.28K	﹤0.01%	2390

Other funds holding CGTX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

BIA

Barry Investment Advisors New Bedford, Massachusetts $478M AUM 23.65% 1-Year Est. Return

Versant Capital Management's CGTX Position: Q2 2026 in Review

Versant Capital Management increased its Cognition Therapeutics (CGTX) stake by 6% in Q2 2026, buying an estimated $218 and bringing the position to 3,257 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Versant Capital Management first reported a position in CGTX in Q4 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Versant Capital Management held 3,257 shares of Cognition Therapeutics worth $3.75K as of Q2 2026.
Versant Capital Management bought 184 Cognition Therapeutics shares in Q2 2026, an estimated $218.
Cognition Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2487 holding.
Versant Capital Management first reported a position in Cognition Therapeutics in Q4 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.